Lu, LuMaezawa, IzumiWeerasekara, SahaniErenler, RamazanNguyen, Thi D.T.Nguyen, JamesSwisher, Luxi ZhangLi, JunJin, Lee-WayRanjan, AlokSrivastava, Sanjay K.Hua, Duy H.2015-05-182015-05-182015-05-18http://hdl.handle.net/2097/19253A new series of fifteen 5-, 6-, and 8-appended 4-methylquinolines were synthesized and evaluated for their neural protective activities. Selected compounds were further examined for their inhibition of glycogen synthase kinase-3β (GSK-3β) and protein kinase C (PKC). Two most potent analogs, compounds 3 and 10, show nanomolar protective activities in amyloid β-induced MC65 cells and enzymatic inhibitory activities against GSK-3β, but poor PKC inhibitory activities. Using normal mouse model, the distribution of the most potent analog 3 in various tissues and possible toxic effects in the locomotors and inhibition of liver transaminases activities were carried out. No apparent decline of locomotor activity and no inhibition of liver transaminases were found. The compound appears to be safe for long-term use in Alzheimer’s disease mouse model.en-USThis Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).Alzheimer’s diseaseAmyloid βGlycogen synthase kinase-3βNeural protective activityProtein kinase CQuinolinesArticle (author version)